Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

Total Voting Rights

6 Jan 2021 10:27

RNS Number : 7656K
Oncimmune Holdings PLC
06 January 2021
 

6 January 2021

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Total Voting Rights

 

 

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.

 

As at 31 December 2020, the Company's issued share capital was 63,662,446 ordinary shares of £0.01 each with voting rights. The Company does not hold any shares in treasury.

 

The above figure of 63,662,446 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAEFKEAKFEFA
Date   Source Headline
16th Oct 20195:01 pmRNSOncimmune welcomes NHS review of cancer screenings
23rd Sep 20197:00 amRNSKey appointments to further strengthen management
20th Sep 20192:32 pmRNSAppointment of Joint Broker
20th Sep 20197:00 amRNSEUR8.5m Credit Facility Secured
18th Sep 20197:00 amRNSOncimmune to Present at 2019 CBIIC
9th Sep 20197:30 amRNSPositive Results for ECLS Trial Presentation
3rd Sep 201912:00 pmRNSECLS at 2019 World Conference for Lung Cancer
1st Aug 201912:00 pmRNSSolebury Trout European Biotech Investor Day
15th Jul 20197:00 amRNSFurther Expansion in Spain for EarlyCDT Lung
4th Jul 201910:38 amRNSCommercialisation Partnership in Russia
2nd Jul 20197:00 amRNSProactive Investors One2One Investor Forum
28th Jun 20197:00 amRNSCommercialisation Agreement in US with Biodesix
26th Jun 20197:00 amRNSBusiness Update
4th Jun 20197:00 amRNSPositive Results for Early Cancer Detection Test
15th May 20197:00 amRNSRegulatory Approval in Israel for EarlyCDT®-Lung
10th May 20197:00 amRNSInitiation of a Multi-Centre Trial in China
17th Apr 20197:00 amRNSHolding(s) in Company
5th Apr 20197:00 amRNSAgreement for Portugal and Spain
2nd Apr 20197:00 amRNSAppointment of Parag Mallick to Scientific Board
1st Apr 20195:19 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSEarlyCDT®-Lung Registered in Columbia
25th Mar 20197:00 amRNSSpanish Private Hospital to Sell EarlyCDT®-Lung
19th Mar 20197:00 amRNSOncimmune acquires Protagen Diagnostics AG
13th Feb 20197:00 amRNSHalf Year Results
31st Jan 20197:00 amRNSNotice of Half Year Results
24th Jan 20197:00 amRNSGrant of Options and PDMR notification
23rd Jan 20197:00 amRNSOncimmune to host Science Day in London today
14th Jan 20197:00 amRNSOncimmune Science Day
20th Dec 20182:13 pmRNSOncimmune signs US distribution agreement
13th Dec 20187:00 amRNSOncimmune appoints new Scientific Board
6th Dec 20184:34 pmRNSSenior Leadership Team Appointments & Board Change
30th Nov 201810:46 amRNSResult of AGM
28th Nov 20187:10 amRNSDistribution Agreements & Registration Outside EU
5th Nov 20187:00 amRNSAnnual Report and Accounts and AGM Notification
31st Oct 20187:00 amRNSResults for the year ended 31 May 2018
1st Oct 20187:00 amRNSBusiness Update
28th Sep 20187:00 amRNSAppointment of Non-Executive Director
25th Sep 20183:45 pmRNSIASLC World Conference on Lung Cancer Presentation
25th Sep 20187:00 amRNSGrant of options
24th Sep 20187:00 amRNSBoard Change
13th Sep 20187:00 amRNSAppointment of Marco Casarin as General Manager
26th Jul 201812:33 pmRNSNotification & Public Disclosure of a Transaction
4th Jun 20187:38 amRNSBusiness Update
24th May 20187:00 amRNSNew Distribution Agreements for EarlyCDT®-Lung Kit
23rd May 20187:00 amRNSOncimmune Publishes Study in PLOS ONE
14th May 20187:00 amRNSOncimmune Launches EarlyCDT®-Liver Test in the US
23rd Apr 20187:00 amRNSPDMR Notification
11th Apr 20182:01 pmRNSHolding(s) in Company
27th Mar 20188:00 amRNSFinal tranche of £10m equity investment
27th Mar 20187:00 amRNSAppointment of Dr Adam Hill as CMO and CSO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.